NEW YORK (GenomeWeb News) — Sysmex Inostics said today that it has inked a collaboration agreement with Bayer Healthcare to develop blood-based companion diagnostics for targeted anti-cancer therapies being developed by Bayer.

Under the agreement, Sysmex Inostics, a subsidiary of Japanese in vitro diagnostics firm Sysmex, will develop blood-based diagnostic tests using its BEAMing technology, an ultra-sensitive digital PCR approach that can detect cancer cell DNA directly from blood.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.